JY
FHTX icon

Jeff Yass’s Foghorn Therapeutics FHTX Stock Holding History

Jeff Yass’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-30,100
Closed -$212K – 12284
2023
Q2 		$212K Buy
+30,100
New +$210K ﹤0.01% 10158
2023
Q1 		– Sell
-35,900
Closed -$229K – 12830
2022
Q4 		$229K Sell
35,900
-1,100
-3% -$8.29K ﹤0.01% 9781
2022
Q3 		$317K Buy
+37,000
New +$476K ﹤0.01% 9653
2022
Q1 		– Sell
-41,400
Closed -$947K – 13271
2021
Q4 		$947K Buy
+41,400
New +$595K ﹤0.01% 7445

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Jeff Yass's FHTX Position: Q2 2026 in Review

Jeff Yass sold out of Foghorn Therapeutics (FHTX) in Q2 2026, closing a stake of 11,637 shares — an estimated $55.6K sold.

Jeff Yass first reported a position in FHTX in Q4 2020 and held it in 11 quarters. The position peaked at $566K in Q4 2020. 102 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • Jeff Yass reported no remaining Foghorn Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jeff Yass sold 11,637 Foghorn Therapeutics shares in Q2 2026, an estimated $55.6K.
  • Jeff Yass first reported a position in Foghorn Therapeutics in Q4 2020 and held it in 11 quarters.
  • Jeff Yass's Foghorn Therapeutics position peaked at $566K in Q4 2020.
  • 102 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.